| Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis |
69 |
| Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR |
67 |
| Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX |
60 |
| Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial |
43 |
| The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis |
40 |
| Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up |
33 |
| Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in he United States |
29 |
| Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2 |
28 |
| From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives |
28 |
| Thrombopoietin receptor agonists: ten years later |
27 |
| Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab |
24 |
| THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents |
23 |
| Hypoxia modulates the purine salvage pathway and decreases red blood cell and supernatant levels of hypoxanthine during refrigerated storage |
21 |
| Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients |
21 |
| Immobilized fibrinogen activates human platelets through glycoprotein VI |
21 |
| Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry |
20 |
| Introducing high-throughput sequencing into mainstream genetic diagnosis practice in inherited platelet disorders |
20 |
| Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation |
19 |
| State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019 |
19 |
| Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions |
18 |
| Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion |
18 |
| The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017 |
18 |
| Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older |
18 |
| Fecal microbiota transplantation before or after allogeneic hematopoietic transplantation in patients with hematologic malignancies carrying multidrug-resistance bacteria |
18 |
| Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life |
17 |
| Clinical implications of subclonal TP53 mutations in acute myeloid leukemia |
17 |
| Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan |
17 |
| The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project |
16 |
| Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia |
16 |
| CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth |
16 |
| European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when |
16 |
| Clinical and biological features in PIEZO1-hereditary xerocytosis and Gardos channelopathy: a retrospective series of 126 patients |
16 |
| A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy |
16 |
| Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study |
15 |
| Epstein-Barr virus-associated primary nodal T/NK-cell lymphoma shows a distinct molecular signature and copy number changes |
15 |
| Frequency, risk actors, and impact on mortality of arterial thromboembolism in patients with cancer |
15 |
| Clonal hematopoiesis and risk of acute myeloid leukemia |
15 |
| PD-L1(+) tumor-associated macrophages and PD-1(+) tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma |
15 |
| Benefits and pitfalls of pegylated interferon-alpha 2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study |
15 |
| Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI |
14 |
| Genomic landscape of pediatric B-other acute lymphoblastic leukemia in a consecutive European cohort |
14 |
| The early expansion of anergic NKG2A(pos)/CD56(dim)/CD16(neg) natural killer represents a therapeutic target in haploidentical hematopoietic stem cell transplantation |
14 |
| Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target |
14 |
| Emerging disease-modifying therapies for sickle cell disease |
14 |
| Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients |
14 |
| Constitutional SAMD9L mutations cause familial myelodysplastic syndrome and transient monosomy 7 |
14 |
| Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective |
14 |
| Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia |
14 |
| Treatment outcomes and prognostic factors in adult patients with secondary hemophagocytic lymphohistiocytosis not associated with malignancy |
14 |
| The many faces of IKZF1 in B-cell precursor acute lymphoblastic leukemia |
14 |
